Final results of the initial public offering of Herantis Pharma

Final results of the initial public offering of Herantis Pharma
Herantis Pharma Plc
Company release 4 June 2014 at 4 p.m.
Not  for release or distribution  or publication in whole  or in part in or into
Australia,  South Africa, Hong Kong,  Japan, Canada or The  United States or any
other  jurisdiction in which  the release, distribution  or publication would be
Herantis  Pharma Plc  ("Herantis" or  "company") announced  by way  of a company
release  published on  12 May 2014 a  directed share  issue in which the company
offers  for subscribing a  maximum of 1,600,000 new  shares. In its release, the
company  also announced that  it will apply  for listing of  its shares on First
North  Finland  ("First  North"),  a  multilateral  trading facility operated by
NASDAQ OMX Helsinki Ltd.
The company issued a company release regarding the outcome of the initial public
offering  on 2 June 2014. Investors  subscribed for a  total of 1,384,070 shares
within  the subscription period. The board  of directors of Herantis resolved on
30 May  2014 on the approval of the subscriptions  made and the number of shares
to  be issued. The subscriptions were  approved on condition that the subscribed
shares  are paid up in  accordance with the share  issue terms and conditions no
later than on 2 June 2014.
The  subscription price was EUR  10.50 per share.  In the  share issue, in total
1,364,770 shares were subscribed and paid for in accordance with the share issue
terms  and conditions. Subscriptions which were  not paid for in accordance with
the  share  issue  terms  and  conditions  were  disqualified. Such disqualified
subscriptions  covered  in  total  19,300 shares.  Thus Herantis raises in total
approximately  14.3 million  euro  in  the  share  issue before the deduction of
expenses  and fees arising from the share issue, and the number of issued shares
in the company will increase to 4,058,214 shares in total.
Herantis  has on 12 May 2014 filed an application for admission of the company's
shares  to  trading  on  First  North  with  the  trading code HRTIS. The shares
subscribed  for in the share issue are  expected to be registered with the Trade
Register  on  or  about  6 June  2014, and  trading  in  the company's shares is
expected to commence on or about 11 June 2014.
UB  Securities Ltd acted as the Lead Arranger and as the subscription place. The
company's  Certified  Adviser  under  the  First  North rules is UB Capital Ltd.
Krogerus  Attorneys Ltd acted as legal adviser to the company in connection with
the share issue.
Herantis Pharma Plc
Board of directors
Further information:
Herantis Pharma Plc, Pekka Simula, Managing Director, mobile: +358 40 7300 445
UB   Securities   Ltd,   Herman   Segercrantz,   Head  of  Equities,  telephone:
+358 9 2538 0220, email:
Herantis Pharma Plc
Herantis  Pharma  Plc  is  a  pharmaceutical  company  specialised  in advancing
scientific  research into clinical research aiming  at developing new drugs. The
company  focuses on diseases with an unmet clinical need. These diseases include
for example dry eye syndrome, Parkinson's disease, and secondary lymphedema.
This  release is  not a  prospectus. The  information contained  herein does not
constitute  an offer to  sell or the  solicitation of an  offer to buy nor shall
there  be any sale of  the securities referred to  herein in any jurisdiction in
which  such offer, solicitation or sale would be unlawful prior to registration,
exemption  from registration or  qualification under the  securities laws of any
jurisdiction. Any such offer will be made solely on the basis of a prospectus to
be published and registered with the Finnish Financial Supervisory Authority.
This document is not an offer for sale nor a solicitation of an offer to buy any
securities  in  the  United  States  or  outside the European Economic Area. The
securities  may not be offered  or sold in or  into the United States of America
absent  registration or an exemption from registration under the U.S. Securities
Act  of 1933, as amended. Herantis has not  registered and will not register any
part  of its offering in  the United States nor  will it offer securities to the
public in the United States.
This  communication is  only being  distributed to  and is  directed only at (i)
persons  who are  outside the  United Kingdom,  or (ii) investment professionals
falling  within Article  19(5) of the  Financial Services  and Markets Act 2000
(Financial  Promotion)  Order  2005 (the  "Order")  and  (iii)  high  net  worth
entities,  and other  persons to  whom it  may lawfully be communicated, falling
within  Article  49(2) of  the  Order,  and  (iv)  other  persons to whom it may
otherwise  lawfully be communicated (all such persons together being referred to
as  "relevant persons").  Any investment  or investment  activity to  which this
communication  relates will  only be  available to  and will  only be engaged in
with,  relevant persons. Any person who is  not a relevant person should not act
or rely on this document or any of its contents.
Securities  in the company have not been,  and will not be, registered under the
applicable  securities laws of Australia, Canada or Japan and may not be offered
or  sold within Australia, Canada or Japan or  to, or for the account or benefit
of,   citizens   or  residents  of  Australia,  Canada  or  Japan  except  under
circumstances  which will result in full compliance with the applicable laws and
regulations  promulgated by the relevant regulatory authorities in effect at the
relevant time.
The  company does not offer securities to the  public in any Member State of the
European  Economic Area other than Finland. With respect to each Member State of
the European Economic Area other than Finland (each, a "Relevant Member State"),
no  action has been  undertaken to date  to make an  offer to the  public of the
securities requiring a publication of a prospectus in any Relevant Member State.
As  a  result,  the  shares  may  only  be  offered in Relevant Member States in
circumstances  not requiring  the company  to publish  a prospectus  as provided
under the Directive 2003/71/EC.